.
Isoetharine (1-[ 3,4-dihydroxyphenyl] -2-isopropylamino-1-butanol hydrochloride) is a derivative of isoprenaline and ethylnoradrenaline and has the following formula: It is an effective antagonist of histamine-induced bronchoconstriction in the guinea-pig, and its action is enhanced by the addition of the antihistamine drug thenyldiamine hyrochloride (Lands et al., 1958) . It is readily absorbed along the mucous membranes of the respiratory and gastro-intestinal tracts of the dog (Lands, 1962) .
Bronchilator is a triple-drug aerosol containing isoetharine, phenylephrine (a vasoconstrictor and mild bronchodilator), and thenyldiamine (an antihistamine). American workers (Spielman, 1961; Siegel, 1962; Goldfarb and Romanoff, 1962) have reported the value of the triple aerosol in bronchial asthma, and its freedom from side-effects even in hypertensive patients. The aim of this work is to compare objectively the degree and duration of effect of Bronchilatorl with that of isoprenaline2 and a placebo aerosol3 in a double-blind controlled study.
Material
Patients attending the asthma clinic who had low records of lung-function tests (F.E.V.1 of 1,000 or below over the past two to three years) were selected, and asked to discontinue all tablets for a period of 24 hours prior to the day of study. If, however, they became distressed their usual inhaler could be used and the time noted. The patients co-operated, and on arrival at the unit all were wheezy and most felt tightness in the chest.
The age and sex distribution of the 60 patients who took part in this trial are shown in Table I . Thirty-five had asthma and 25 bronchitis. Of the 44 females, 31 (70%) were asthmatics ; of the 16 males, only 4 (25%) had asthma. Seven females and one male had hypertension, and three of these also had coronary artery disease.
Certain criteria (Higgins, 1957; Williams, 1961 ; Scadding, 1963) (Wright and McKerrow, 1959) .
Part I.-The placebo, isoprenaline, and Bronchilator inhalers, identical in colour, shape, and taste, were labelled A, B, and C. Neither the patient nor the staff involved in the trial were aware of the key to the code during the trial. After initial control measurements of F.E.V.1, F.V.C., P.F.R., pulse, and blood-pressure, three inhalations from the first inhaler were administered. These measurements were then determined at 15 and 30 minutes. The process was then repeated with the other inhalers. Each of the 60 patients participated in six distinct trial sessions of one and a half hours each, four in one day and two during a half-day 24 hours later. Each session consisted of the three treatments, given in turn at half-hourly intervals. The order of the three treatments in each session was predetermined so that each session corresponded to one of the six possible orders in which these treatments could be administered (Table II) . Twenty-eight patients began both the full-day and the half-day sessions at 9 a m. The remaining 32 began the first two sessions at 2 p.m. and the final four at 9 a.m. Patients were encouraged to do their best in every lungfunction test, and repeat measurements were taken whenever necessary. Any undesirable side-effects were noted. significant for P.F.R. measurements. Patients differed significantly in the extent of their improvement after treatments, and 10 cases (17%) improved more with isoprenaline than with Bronchilator. Analysis of lung-function-test improvements for each session showed that the order in which the treatments were given affected the results significantly. The third session had the highest mean improvements for all three tests (F.E.V., 216.8 ml., F.V.C. 365.6 ml., and P.F.R. 328 1., and the fifth session had also high means (F.E.V.1 106.8 ml., F.V.C. 310.7 ml., and P.F.R. 217 1.). The placebo was placed between the two active drugs in these two sessions (see Table II ), and maximum drug and carry-over effects from the previous active drug are evident. The effect of both active drugs lasted more than the 30-minute interval allowed in this stage. Bronchilator as well as after the placebo, but there was no significant change after isoprenaline. Both active drugs were followed by significant reduction (0.1 % level) in blood-pressure, but no change was apparent after the placebo. Part I1. -Fig. 4 shows the mean change in pulse rate following treatments with both active drugs for a period of three hours. An immediate increase in pulse rate is apparent after isoprenaline, followed in 15 minutes by a decrease to a level fluctuating around the baseline. Slowing of pulse rate occurred after Bronchilator and placebo. Fig. 5 that reductions in pressures in the isoprenaline group are consistently greater than those in the Bronchilator group for at least 90 minutes. The difference between the two groups was highly significant for systolic and diastolic reductions (P<0.001 and <0.01 respectively). In the isoprenaline group highly significant reductions in systolic and diastolic blood- 
Discussion
It is appreciated that in patients with obstructive airway disease lung-function tests give varying results throughout the 24 hours, the lowest levels occurring early in the morning (Lewinsohn et al., 1960) . Difficulties also arise when an attempt is made to compare drug treatments in asthma, owing to the variations in response between patients and in the same patient at different times (Hume and Gandevia, 1957) . Also interpretation of lung-function tests is limited unless patients' full co-operation is achieved. These factors were taken into consideration when this trial was designed and every attempt was made to minimize their influence.
It is accepted that asthmatics have reversible obstructive airway disease, whereas in bronchitics the functional obstruction is only partially reversible. In Part I, patients differed significantly in the extent of improvement shown by lung-function tests after treatment. In addition to the expected variation between patients in response to therapy, the difference in the magnitude of improvement between asthmatics and bronchitics could also partly account for this finding.
Although the curves plotted in Figs. 1, 2, and 3 from the data obtained in Part II show the superiority of Bronchilator over isoprenaline for at least two hours, these curves only show the mean improvement differences in lung-function tests and do not reflect the wide differences between patients' response to either drug. Analysis of linear regression for data from 30 to 180 minutes after medication confirmed that the observed differences between Bronchilator and isoprenaline were real and not merely the result of random fluctuation or variation between patients.
The curves for F.E.V., F.V.C., and P.F.R. are similar for both active drugs. This similarity suggests that those measurable improvements in P.F.R. are closely related to corresponding improvements in F.E.V.l and F.V.C. A close correlation between P.F.R. and maximum voluntary ventilation was reported (Higgins, 1957 ; Prime, 1960) , but no such correlation was found between P.F.R. and F.E.V. measurements (Prime, 1960) . Bouhuys (1957 Bouhuys ( , 1960 Blood-pressure reductions after Bronchilator have been reported (Herschfus et al., 1951 ; Spielman, 1961) . The former found no change in pulse pressure in five patients. Goldfarb and Romanoff (1962) claimed that large reductions in bloodpressures occurred after Bronchilator (systolic 20-30 mm., diastolic 10-20 mm. Hg), and they suggested that their findings warranted further study. In the present series reduction in systolic but not in diastolic blood-pressure was statistically significant (2 % level) after Bronchilator. The mean maximum blood-pressure reductions, however, were small (systolic 6.4 mm., diastolic 2.8 mm. Hg), and were similar in extent in hypertensive and normotensive patients.
Summary
Lung-function tests in 35 asthmatics and 25 bronchitics were used in a double-blind controlled trial to compare the effect and duration of a new sympathomimetic aerosol-isoetharine (Bronchilator) with those of isoprenaline.
The differences between improvements in lung-function tests following both active drugs and the placebo were highly significant. The means of maximum improvements in lungfunction tests were much more pronounced in asthmatics than in bronchitics, and were greater after Bronchilator than after isoprenaline. Maximum improvement in F.E.V.1 occurred 30 to 45 minutes after Bronchilator and the effect was still significant at 105 minutes. For isoprenaline, maximum improvement occurred at 15 minutes and the effect was still significant at 90 minutes. The improvement shown in lung-function tests after Bronchilator was greater than that following isoprenaline for at least two hours. The observed difference in improvements between the two drugs was real and not due to random fluctuation or variation between patients.
A mean increase in pulse rate for 15 minutes followed isoprenaline. This was not demonstrated after Bronchilator. Reductions in blood-pressure occurred after both active drugs, and were consistently greater after isoprenaline for at least 90 minutes. 
